Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$64.33K$64.33Kno prior Q2 2018 on file Net Income-$116.82K-$116.82KN/M vs Q2 2018 EPS Diluted$0.00$0.00— vs Q2 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Operating Cash Flowderived$7,939N/M Margins · derivedGross margin73.8%
Operating margin-157.5%
Net margin-181.6%
ended Jun 30, 2019 · filed Aug 5, 2019 · 36 d after period end